December 5, 2014 : Episode 1

Latest News & Insight: December 5, 2014

Video

Related Videos
Carmen Guerra, MD, MSCE, FACP
Kara N. Maxwell, MD, PhD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Eric Vallieres, MD, FRCSC
Josep Maria Piulats Rodriguez, MD, PhD
Benjamin Levy, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
Related Content
In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Anne Favret, MD

Examining the Evolution of Treatment With CDK4/6 Inhibitors in Metastatic Breast Cancer

April 12th 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
James Chih-Hsin Yang, MD, PhD, National Taiwan University Hospital, National Taiwan University Cancer Centre

Savolitinib/Osimertinib Yields Responses in EGFR-Mutant, MET-Amplified, Osimertinib-Resistant NSCLC

April 10th 2024
Article
Ebrahim Delpassand, MD, of Excel Diagnostics and Nuclear Oncology Center

PSMA-Directed Targeted Alpha Therapy Shows Activity in Heavily Pretreated Metastatic CRPC

April 10th 2024
Article